Zimmer Biomet Holdings, Inc. $ZBH Stake Lifted by Corbyn Investment Management Inc. MD

Corbyn Investment Management Inc. MD increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,047 shares of the medical equipment provider’s stock after purchasing an additional 574 shares during the period. Corbyn Investment Management Inc. MD’s holdings in Zimmer Biomet were worth $3,014,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $204,000. Allworth Financial LP raised its position in Zimmer Biomet by 12.0% in the first quarter. Allworth Financial LP now owns 2,065 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 222 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Zimmer Biomet by 4.7% in the 1st quarter. New York State Common Retirement Fund now owns 181,763 shares of the medical equipment provider’s stock valued at $20,572,000 after acquiring an additional 8,124 shares during the last quarter. CWM LLC boosted its position in shares of Zimmer Biomet by 2.3% during the 1st quarter. CWM LLC now owns 8,078 shares of the medical equipment provider’s stock valued at $914,000 after purchasing an additional 180 shares in the last quarter. Finally, LRI Investments LLC grew its stake in shares of Zimmer Biomet by 29.3% in the 1st quarter. LRI Investments LLC now owns 1,094 shares of the medical equipment provider’s stock worth $124,000 after purchasing an additional 248 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Down 0.2%

NYSE ZBH opened at $88.52 on Wednesday. The stock’s 50 day moving average is $99.46 and its two-hundred day moving average is $97.29. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.72. The company has a market capitalization of $17.54 billion, a price-to-earnings ratio of 21.54, a PEG ratio of 2.29 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ZBH shares. Rothschild & Co Redburn started coverage on Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective for the company. Johnson Rice set a $112.00 target price on Zimmer Biomet in a research report on Wednesday, November 5th. Royal Bank Of Canada decreased their price target on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. UBS Group cut their price objective on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $109.00.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.